You are here

Galectin-3 and incident cognitive impairment in REGARDS, a cohort of blacks and whites.

TitleGalectin-3 and incident cognitive impairment in REGARDS, a cohort of blacks and whites.
Publication TypeJournal Article
Year of Publication2018
AuthorsVenkatraman, A, Callas, P, McClure, LA, Unverzagt, F, Arora, G, Howard, V, Wadley, VG, Cushman, M, Arora, P
JournalAlzheimers Dement (N Y)
Date Published2018

Introduction: The relationship between serum galectin-3 and incident cognitive impairment was analyzed in the Reasons for Geographic and Racial Differences in Stroke study.Methods: Baseline galectin-3 was measured in 455 cases of incident cognitive impairment and 546 controls. Galectin-3 was divided into quartiles based on the weighted distribution in the control group, and the first quartile was the referent.Results: There was an increasing odds of cognitive impairment across quartiles of galectin-3 (odds ratios, 1.00 [0.68-1.46], 1.45 [1.01-2.10], and 1.58 [1.10-2.27] relative to the quartile 1; trend = .003) in an unadjusted model, which persisted after adjusting for age, sex, and race ( = .004). Adjustment for cardiovascular risk factors greatly attenuated this association (odds ratios, 0.97 [0.60-1.57], 1.52 [0.94-2.46], and 1.27 [0.76-2.12];  = .15). The association differed by diabetes status ( interaction, .007). Among nondiabetics (293 cases, 411 controls), those with galectin-3 in the fourth compared with first quartile had an odds ratio of 1.6 (0.95-2.99; trend, .02). In diabetics, the odds ratio was 0.23 (0.04-1.33).Discussion: Serum galectin-3 was associated with increased risk of incident cognitive impairment in a large cohort study of blacks and whites but only in nondiabetics.

Alternate JournalAlzheimers Dement (N Y)
PubMed ID29756004
PubMed Central IDPMC5944416